LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "samumed llc" as a keyword



Photo by dawson2406 from unsplash

SAT0552 Clinical outcomes from a randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, injectable, WNT pathway inhibitor (SM04690) for the treatment of knee osteoarthritis: week 26 interim analysis

Sign Up to like & get
recommendations! Published in 2017 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2017-eular.6382

Abstract: Background Knee osteoarthritis (OA) is characterized by pain, disability and joint deformity due to degradation of articular cartilage and bone remodeling. The Wnt signaling pathway has a role in these cellular processes, and it is… read more here.

Keywords: samumed llc; clinical outcomes; analysis; treatment ... See more keywords
Photo by cokdewisnu from unsplash

THU0046 Small molecule inhibitor of the wnt pathway (SM04755) as a potential topical treatment for psoriasis

Sign Up to like & get
recommendations! Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.4752

Abstract: Background Psoriasis (PSO) is an autoimmune disease, causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin cells1. Wnt signalling plays an important role in PSO, regulating inflammation and keratinocyte proliferation. SM04755,… read more here.

Keywords: compared vehicle; sm04755; samumed llc; vehicle ... See more keywords
Photo by taylorkeeran from unsplash

FRI0534 Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a wnt pathway inhibitor, sm04690, for knee osteoarthritis treatment

Sign Up to like & get
recommendations! Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.6036

Abstract: Background SM04690, a small molecule intra-articular (IA) Wnt pathway inhibitor is in development as a potential disease modifying knee osteoarthritis drug. A phase 2, 52 week, randomised controlled trial evaluated changes in Western Ontario and McMaster… read more here.

Keywords: samumed llc; concordance; mjsw; pain function ... See more keywords
Photo by munibsaad from unsplash

OP0072 INHIBITION OF CLK2 AND DYRK1A BY SM04690 AS A NOVEL MOLECULAR REGULATOR OF WNT SIGNALING, CHONDROGENESIS, AND INFLAMMATION, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.5202

Abstract: Background In the synovial joint, Wnt pathway upregulation contributes to osteoarthritis (OA) by increasing osteocyte differentiation, cartilage thinning, and inflammation. SM04690, a novel small molecule, has previously demonstrated potential OA disease-modifying effects through Wnt pathway… read more here.

Keywords: employee samumed; samumed llc; shareholder samumed; llc employee ... See more keywords
Photo by dawson2406 from unsplash

OP0137 OPTIMIZING SUBJECT SELECTION IN KNEE OSTEOARTHRITIS CLINICAL TRIALS BY RADIOGRAPHIC JOINT SPACE WIDTH: POST-HOC CLINICAL RESPONSE ANALYSIS FROM A PHASE 2B TRIAL OF WNT PATHWAY INHIBITOR, SM04690

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.5219

Abstract: Background Knee osteoarthritis (OA) trial radiographic inclusion criteria usually comprises Kellgren-Lawrence (KL) grading, which mixes features such as osteophytes and joint space narrowing and leads to study population heterogeneity. Selecting subjects with baseline medial joint… read more here.

Keywords: post hoc; samumed llc; analysis; joint space ... See more keywords
Photo by gvchana from unsplash

FRI0430 THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (LOR; SM04690), WHICH MODULATES THE WNT PATHWAY, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL

Sign Up to like & get
recommendations! Published in 2020 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2020-eular.6467

Abstract: Background: Lorecivivint (LOR; SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor that modulates the Wnt pathway1 and has demonstrated some beneficial effects on patient-reported outcomes (PROs) relative to placebo (PBO) in two Phase 2 knee… read more here.

Keywords: samumed llc; lor; phase; post hoc ... See more keywords

FRI0380 ITEMS DRIVING WOMAC PAIN SUBSCORE CHANGES DUE TO LORECIVIVINT, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS OF PHASE 2B TRIAL DATA

Sign Up to like & get
recommendations! Published in 2020 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2020-eular.6476

Abstract: Knee osteoarthritis (OA) is a disease characterized by pain, loss of function, and structural deformities, leading to a heterogeneous disease state that can confound patient-reported outcomes (PROs). The Western Ontario and McMaster Universities Osteoarthritis Index… read more here.

Keywords: womac; samumed llc; pain; effect ... See more keywords